Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 10, 2016 8:25 PM ET


Company Overview of Sucampo Pharmaceuticals, Inc.

Executive Profile

Peter S. Greenleaf

Chairman and Chief Executive Officer, Sucampo Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 4 Board Members in 4 different organizations across 9 different industries.

See Board Relationships
As of Fiscal Year 2014


Mr. Peter S. Greenleaf has been the Chairman and Chief Executive Officer of Sucampo Pharmaceuticals, Inc. since January 1, 2016 and March 03, 2014 respectively. Mr. Greenleaf served as Chief Executive Officer of Histogenics Corporation from June 10, 2013 to February 28, 2014 and served as its President. Mr. Greenleaf served as President of MedImmune, LLC (also known as MedImmune, Inc.). Mr. Greenleaf also served as President of MedImmune Ventures, a wholly owned venture ...

Corporate Headquarters

4520 East West Highway
Bethesda, Maryland 20814

United States

Phone: 301-961-3400
Fax: 301-961-3440

Board Members Memberships

Chairman and Chief Executive Officer
Director, Member of Compensation Committee and Member of Audit Committee


Saint Joseph's University
Western Connecticut State University

Other Affiliations

Annual Compensation

Total Annual Compensation$440,192

Stocks Options

All Other Compensation$2,025
Unexercisable Options$1,000,000
Unexercisable Options Value$6,656,000
Total Value of Options$6,656,000
Total Number of Options$1,000,000

Total Compensation

Total Annual Cash Compensation$811,979
Total Short Term Compensation$440,192
Other Long Term Compensation$2,025
Total Calculated Compensation$5,650,759

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup


Peter M. Hecht Ph.D. Co-Founder, Chief Executive Officer and Director
Ironwood Pharmaceuticals, Inc.
Mark R. Baker J.D.Chief Executive Officer, Director and Member of Science & Strategy Committee
Progenics Pharmaceuticals, Inc.
Craig A. Wheeler Chief Executive Officer, President and Executive Director
Momenta Pharmaceuticals Inc.
Douglas L. Drysdale Chairman, Chief Executive Officer and President
Pernix Therapeutics Holdings, Inc.
Allan Oberman Chief Executive Officer and Director
Sagent Pharmaceuticals, Inc.
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Sucampo Pharmaceuticals, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at